Skip to main content
SpringerLink
Log in

Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL‐4R signaling induced by both IL‐4 and IL‐13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Licari A, Manti S, Castagnoli R, Parisi GF, Salpietro C, Leonardi S, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21:215–37.

    Article  PubMed  Google Scholar 

  2. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15:271–82.

    Article  CAS  PubMed  Google Scholar 

  3. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425–37.

    Article  CAS  PubMed  Google Scholar 

  4. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10:225–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701–38.

    Article  CAS  PubMed  Google Scholar 

  7. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50:5–14.

    Article  CAS  PubMed  Google Scholar 

  8. Keegan AD, Nelms K, White M, Wang LM, Pierce JH, Paul WE. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell. 1994;76:811–20.

    Article  CAS  PubMed  Google Scholar 

  9. Huang SC, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macro-phage alternative activation. Immunity. 2016;45:817–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol. 2008;9:25–33.

    Article  CAS  PubMed  Google Scholar 

  11. Tanaka Y, Hamano S, Gotoh K, Murata Y, Kunisaki Y, Nishikimi A, et al. T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2. Nat Immunol. 2007;8:1067–75.

    Article  CAS  PubMed  Google Scholar 

  12. Noval Rivas M, Burton OT, Wise P, Charbonnier LM, Georgiev P, Oettgen HC, et al. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015;42:512–23.

    Article  CAS  PubMed  Google Scholar 

  13. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997;337:1720–5.

    Article  CAS  PubMed  Google Scholar 

  14. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccines Immunother. 2019;15:2129–39.

    Article  Google Scholar 

  15. Dupilumab FDA Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed 19 Jan 2020.

  16. Dupilumab EMA Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed 19 Jan 2020.

  17. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.

    Article  PubMed  CAS  Google Scholar 

  18. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.

    Article  CAS  PubMed  Google Scholar 

  19. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–303.

    Article  CAS  PubMed  Google Scholar 

  20. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to cyclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083–101.

    Article  PubMed  CAS  Google Scholar 

  21. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019. https://doi.org/10.1001/jamadermatol.2019.3336.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.18476.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2019. https://doi.org/10.1111/bjd.18434.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(1778–80):e1.

    Google Scholar 

  25. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143–51.

    Article  CAS  PubMed  Google Scholar 

  27. Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120–2.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180:1248–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(158):67.e1.

    Google Scholar 

  30. Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, et al. Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. Dermatol Ther (Heidelb). 2019;9:799–805.

    Article  Google Scholar 

  31. Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2019. https://doi.org/10.1007/s40257-019-00478-y.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD). https://clinicaltrials.gov/ct2/show/NCT03345914. Accessed 19 Jan 2020.

  33. Igelman S, Kurta AO, Sheikh U, McWilliams A, Armbrecht E, Jackson Cullison SR, et al. Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.10.010.

    Article  PubMed  Google Scholar 

  34. de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.18730.

    Article  PubMed  Google Scholar 

  35. Johnson BB, Beck LA, Mustafa SS. Remarkable response to dupilumab in a 5-year-old patient with severe, recalcitrant atopic dermatitis. JAAD Case Rep. 2019;5:605–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Varma A, Tassavor M, Levitt J. The utility of dupilumab for use in the pediatric population. JAAD Case Rep. 2019;5:943–4.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35:737–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–85.

    Article  CAS  PubMed  Google Scholar 

  39. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–96.

    Article  CAS  PubMed  Google Scholar 

  40. Maspero J, Fitzgerald M, Pavord I, Wenzel S, Zhang B, Maroni J, Rowe P, et al. Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study. Chest. 2018;154(4 Suppl):25A–7A.

    Article  Google Scholar 

  41. Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL). https://clinicaltrials.gov/ct2/show/NCT03346434. Accessed 19 Jan 2020.

  42. Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). https://clinicaltrials.gov/ct2/show/NCT02612454. Accessed 19 Jan 2020.

  43. Dupilumab Phase 4 Study (DRS). https://clinicaltrials.gov/ct2/show/NCT03411837. Accessed 19 Jan 2020.

  44. BioDay Registry: Data Collection Regarding Dupixent in Patients With Atopic Dermatitis in Daily Practice (BioDay). https://clinicaltrials.gov/ct2/show/NCT03549416. Accessed 19 Jan 2020.

  45. Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE). https://clinicaltrials.gov/ct2/show/NCT03428646. Accessed 19 Jan 2020.

  46. Evaluation of Dupilumab in Children With Uncontrolled Asthma (VOYAGE).https://clinicaltrials.gov/ct2/show/NCT02948959. Accessed 19 Jan 2020.

  47. Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion). https://clinicaltrials.gov/ct2/show/NCT03560466. Accessed 19 Jan 2020.

  48. Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma. https://clinicaltrials.gov/ct2/show/NCT03782532. Accessed 19 Jan 2020.

  49. Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE). https://clinicaltrials.gov/ct2/show/NCT02134028. Accessed 19 Jan 2020.

  50. Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up). https://clinicaltrials.gov/ct2/show/NCT03620747. Accessed 19 Jan 2020.

  51. Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med. 2016;22:1013–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lai PS, Massoud AH, Xia M, Petty CR, Cunningham A, Chatila TA, et al. Gene-environment interaction between an IL4R variant and school endotoxin exposure contributes to asthma symptoms in inner-city children. J Allergy Clin Immunol. 2018;141(794–96):e3.

    Google Scholar 

  53. Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Adolescents and Adults With Asthma (I-DAG). https://clinicaltrials.gov/ct2/show/NCT03694158. Accessed 19 Jan 2020.

  54. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35–50.

    Article  CAS  PubMed  Google Scholar 

  55. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Licari A, Brambilla I, De Filippo M, Poddighe D, Castagnoli R, Marseglia GL. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017;11:855–65.

    Article  CAS  PubMed  Google Scholar 

  57. Licari A, Caimmi S, Bosa L, Marseglia A, Marseglia GL, Caimmi D. Rhinosinusitis and asthma: a very long engagement. Int J Immunopathol Pharmacol. 2014;27:499–508.

    Article  CAS  PubMed  Google Scholar 

  58. Marseglia GL, Pagella F, Licari A, Scaramuzza C, Marseglia A, Leone M, et al. Acute isolated sphenoid sinusitis in children. Int J Pediatr Otorhinolaryngol. 2006;70:2027–31.

    Article  PubMed  Google Scholar 

  59. Montella S, Baraldi E, Cazzato S, Aralla R, Berardi M, Brunetti LM, et al. Severe asthma features in children: a case-control online survey. Ital J Pediatr. 2016;42:9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Simpson E, Guttman-Yassky E, Margolis D. Chronicity, comorbidity, and life course impairment in atopic dermatitis: insights from a cross-sectional study in US adults. From 25th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, 2016.

  61. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123:144–51.

    Article  PubMed  Google Scholar 

  62. Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(171–77):e1.

    Google Scholar 

  63. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469–79.

    Article  CAS  PubMed  Google Scholar 

  64. Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: a randomized trial. J Allergy Clin Immunol. 2017;140(1024):31.e14.

    Google Scholar 

  65. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–50.

    Article  CAS  PubMed  Google Scholar 

  66. Licari A, Votto M, D’Auria E, Castagnoli R, Caimmi SME, et al. eosinophilic gastrointestinal diseases in children: a practical review. Curr Pediatr Rev. 2019. https://doi.org/10.2174/1573396315666191022154432.

    Article  PubMed  Google Scholar 

  67. Blanchard C, Stucke EM, Rodriguez-Jimenez B, Burwinkel K, Collins MH, Ahrens A, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol. 2011;127:208–217.e1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–22.e10.

    Article  PubMed  CAS  Google Scholar 

  69. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE). https://clinicaltrials.gov/ct2/show/NCT03633617. Accessed 19 Jan 2020.

  70. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141:41–58.

    Article  CAS  PubMed  Google Scholar 

  71. Mathias CB, Hobson SA, Garcia-Lloret M, Lawson G, Poddighe D, Freyschmidt EJ, et al. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. J Allergy Clin Immunol. 2011;127:795–805.e1–6.

    Article  CAS  PubMed  Google Scholar 

  72. Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48:825–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract. 2019;7:673–4.

    Article  PubMed  Google Scholar 

  74. Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy. https://clinicaltrials.gov/ct2/show/NCT03793608. Accessed 19 Jan 2020.

  75. Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy). https://clinicaltrials.gov/ct2/show/NCT03682770. Accessed 19 Jan 2020.

  76. Dupilumab and Milk OIT for the Treatment of Cow’s Milk Allergy. https://clinicaltrials.gov/ct2/show/NCT04148352. Accessed 19 Jan 2020.

  77. Caproni M, Cardinali C, Giomi B, Antiga E, D’Agata A, Selvaggi W, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci. 2004;36:57e59.

    Article  CAS  Google Scholar 

  78. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109:694e700.

    Article  Google Scholar 

  79. Ferrante G, Scavone V, Muscia MC, Adrignola E, Corsello G, Passalacqua G, et al. The care pathway for children with urticaria, angioedema, mastocytosis. World Allergy Organ J. 2015;8:5.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(1659–61):e1.

    Google Scholar 

  81. Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (CUPID). https://clinicaltrials.gov/ct2/show/NCT04180488. Accessed 19 Jan 2020.

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review.

Author information

Author notes

  1. Amelia Licari and Riccardo Castagnoli are equally contributing first co-authors.

Authors and Affiliations

  1. Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, viale Golgi 19, 27100, Pavia, Italy

    Amelia Licari, Riccardo Castagnoli, Alessia Marseglia, Francesca Olivero, Martina Votto & Gian Luigi Marseglia

  2. Allergy Clinic, Casa di Cura Villa Montallegro, Genova, Italy

    Giorgio Ciprandi

Authors
  1. Amelia Licari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riccardo Castagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessia Marseglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesca Olivero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martina Votto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giorgio Ciprandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gian Luigi Marseglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AL had the idea for the article. RC, AM, FO and MV performed the literature search and data analysis. The first draft of the manuscript was written by AL and RC, then GC and GLM critically revised the work. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Amelia Licari.

Ethics declarations

Funding

None to declare.

Conflict of interest

Amelia Licari, Riccardo Castagnoli, Alessia Marseglia, Francesca Olivero, Martina Votto, Giorgio Ciprandi, and Gian Luigi Marseglia have no conflict of interest directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Licari, A., Castagnoli, R., Marseglia, A. et al. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Pediatr Drugs 22, 295–310 (2020). https://doi.org/10.1007/s40272-020-00387-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-020-00387-2

Search

Navigation